Glenmark Inks $1.1 Billion Deal with China’s Hengrui for Next-Gen Cancer Drug
Glenmark Seals $1.1 Billion Cancer Drug Deal with China’s Hengrui, Making $18M Upfront Payment Mumbai, September 24, 2025 — Glenmark Pharmaceuticals, through its wholly-owned subsidiary Glenmark Specialty S.A., has entered into a landmark licensing and collaboration agreement with China’s Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody-drug conjugate (ADC). The move is a […]
Glenmark Inks $1.1 Billion Deal with China’s Hengrui for Next-Gen Cancer Drug Read More »










